Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Proto-oncogene MET alterations are increasingly recognized in tumorigenesis.
• MET encodes the c-MET receptor tyrosine kinase, crucial for cell growth, survival, and migration.
• Aberrant c-MET signaling, via mutations or amplification, fuels cancer proliferation and invasion.

Purpose of the Study:

• To review key MET alterations including gene amplification, fusions, and exon 14 skipping.
• To examine the prevalence of these MET alterations across diverse cancer types.
• To discuss the clinical significance of c-MET as a therapeutic target.

Main Methods:

• Literature review of recent research on MET alterations in cancer.
• Analysis of MET mutation, amplification, fusion, and exon 14 skipping prevalence.
• Synthesis of clinical significance and therapeutic targeting of c-MET.

Main Results:

• MET alterations are implicated in multiple cancers beyond non-small cell lung cancer (NSCLC).
• Specific alterations like gene amplification, fusions, and exon 14 skipping deletions are highlighted.
• Prevalence data across various tumor types are examined.

Conclusions:

• c-MET represents a significant therapeutic target in oncology.
• Understanding MET alterations is crucial for developing targeted treatment strategies.
• Gaps in knowledge necessitate further research for alternative therapeutic approaches.